To access this element change to forms mode OFF
Grant Award View - GA52644
Targeting BCL-2 in estrogen receptor positive breast cancer
GA ID:
GA52644
Agency:
Cancer Australia
Approval Date:
16-Apr-2019
Publish Date:
2-Jul-2019
Category:
Cancer
Grant Term:
29-Apr-2019 to 28-Apr-2022
Value (AUD):
$599,562.00
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
CA 18/19 Improved cancer control
Grant Program:
2018 Priority-driven Collaborative Cancer Research Scheme
Grant Activity:
Targeting BCL-2 in estrogen receptor positive breast cancer
Purpose:
Most ER-positive (ER+) breast cancers contain high levels of BCL-2, a protein that helps keep cancer cells alive. A potent BCL-2 inhibitor, venetoclax, is showing promise in treating blood cancers. The Investigators previous work indicated that BCL-2 could also be active in patients with ER+ breast cancer. This project will use preclinical (laboratory) models in parallel with an early phase clinical trial to test the effectiveness of adding venetoclax to current ‘gold standard’ breast cancer therapy.
GO ID:
GO Title:
2018 PdCCRS Project Grants for funding commencing 2019
Internal Reference ID:
2018 PdCCRS
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
No
Confidentiality - Outputs:
No
Grant Recipient Details
Recipient Name:
The Walter and Eliza Hall Institute of Medical Research
Recipient ABN:
12 004 251 423
Grant Recipient Location
Suburb:
Parkville
Town/City:
Melbourne
Postcode:
3052
State/Territory:
VIC
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
National
Postcode:
Multiple
Country:
AUSTRALIA